ARTHRITIS ADVISORY COMMITTEE

April 11, 2000

Briefing Information

Enbrel (etanecept) License Number 1132, SBLA

Briefing Information, Division of Clinical Trial Design and Analysis, OTRR, Center for Biological Evaluation and Research

Disclaimer

The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document

Briefing Information, Immunex